Research Updates

Back to feed
PubMed

High importance

Oct 1, 2026

c-KIT expands the tool kit for treating arteriovenous malformation.

View original source

Why it matters

Understanding the mechanism by which c-KIT contributes to HHT-related vascular abnormalities could lead to novel targeted therapies, improving management and outcomes for patients suffering from AVMs associated with HHT.

Objective

To investigate the role of c-KIT in vascular pathology associated with Hereditary Hemorrhagic Telangiectasia (HHT) and its potential as a therapeutic target.

Results

Both studies identified c-KIT as a key mediator in the vascular complications of HHT. Pharmacological inhibition of c-KIT was shown to reduce pathological angiogenesis and ameliorate symptoms associated with HHT.

Methods

Two independent studies were conducted: one examined the role of SMAD4 loss in c-KIT activation within endothelial cells, while the other explored ALK1 loss in a mouse model to characterize the c-KIT+ endothelial state in brain arteriovenous malformations (AVMs).

Limitations

The studies were preclinical, focusing on mouse models which may not fully replicate human pathology. Further research is necessary to validate these findings in clinical settings and determine the safety and efficacy of c-KIT inhibition in human subjects.

For your doctor:

PMID: 42820304

DOI: 10.1172/JCI210364

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is characterized by fragile, enlarged vessels with arteriovenous connections, which can form arteriovenous malformations (AVMs) that are prone to rupture. It is driven by mutations in TGF‑β pathway genes that disrupt endothelial cell responses and blood vessel remodeling. Two studies published in this issue of the JCI identify c‑KIT as a central mediator of HHT vascular pathology. Gahn et al. showed that SMAD4 loss derepressed c‑KIT, whose activity in the junctional mechanosensory receptor complex of endothelial cells reset the fluid shear stress set point to drive maladaptive vascular remodeling. Drapé et al. demonstrated that ALK1 loss in a mouse model of HHT induced a regional pro‑angiogenic c‑KIT+ endothelial state in brain AVMs. Both studies showed that pharmacologic c-KIT inhibition mitigated disease, revealing an unexpected, potentially ligand‑independent role for c‑KIT and highlighting a promising therapeutic target.